Windward Bio Launches Global Phase 2 Asthma Trial for SKB378/WIN378 Following Regulatory Approval in Collaboration with <a href="https://laohu8.com/S/002422">Sichuan Kelun</a>-Biotech and Harbour BioMed
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has announced that its partner Windward Bio AG has initiated a global Phase 2 clinical trial for the asthma treatment SKB378/WIN378, following the successful approval of an IND application by the National Medical Products Administration (NMPA) in January 2025. This development comes under the exclusive license agreement with Windward Bio, which includes the research, development, manufacturing, and commercialization of SKB378/WIN378 globally, except for Greater China and several Southeast and West Asian countries. The Phase 2 POLARIS trial, a randomized, double-blind, placebo-controlled study, aims to evaluate the dosing, safety, and efficacy of the novel monoclonal antibody in asthma patients, with initial data expected by mid-2026. Additional trials for COPD are planned for 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN36078) on July 23, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.